GERN Geron Corp.

Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018

Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018

MENLO PARK, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to provide an update on the imetelstat collaboration with Janssen Biotech, Inc. (Janssen) on Thursday, September 27th at 8:00 a.m. ET.

Participants may access the conference call live via telephone by dialing domestically +1 (877) 303-9139 or internationally +1 (760) 536-5195. The passcode is 7987354. Participants are advised to dial in at least 10 minutes prior to minimize any delay in joining the call. A live, listen-only webcast will also be available on the Company’s website at . If you are unable to listen to the live call, an archived webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit

CONTACT:

Suzanne Messere

Investor and Media Relations



CG Capital

877-889-1972

EN
27/09/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Geron Corp.

Geoffrey Von Der Ahe ... (+2)
  • Geoffrey Von Der Ahe
  • Robert Driscoll
 PRESS RELEASE

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial ...

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securiti...

 PRESS RELEASE

Geron Plans to Present at Upcoming Investor Conferences

Geron Plans to Present at Upcoming Investor Conferences FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: TD Cowen 46th Annual Healthcare ConferenceFireside Chat on Monday, March 2 at 1:10 p.m. ET in Boston, MABarclays 28th Annual Global Healthcare ConferenceFireside Chat on Tuesday, March 10 at 10:30 a.m. ET in Miami, FLLeerin...

Wedbush Research
  • Wedbush Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch